Section Arrow
Quote
SUPN.NASDAQ
- Supernus Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/04 10:29 EDT
Last
 31.98
-0.09 (-0.28%)
Day High 
32.55 
Prev. Close
32.07 
1-M High
33.7 
Volume 
212.57K 
Bid
13.46
Ask
31.98
Day Low
31.745 
Open
32.14 
1-M Low
30.83 
Market Cap 
1.80B 
Currency USD 
P/E 28.89 
%Yield -- 
10-SMA 31.79 
20-SMA 32.25 
50-SMA 32.18 
52-W High 40.28 
52-W Low 25.655 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.11/1.09
Enterprise Value
1.82B
Balance Sheet
Book Value Per Share
18.41
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
661.82M
Operating Revenue Per Share
10.90
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands0.5387+0.0535+11.03%-- 
RGCRegencell Bioscience Holdings Limited22.99+12.63+121.91%-- 
CGCCanopy Growth Corp1.28+0.09+7.56%-- 
IXHLIncannex Healthcare0.2094+0.0025+1.21%-- 
HLNHaleon plc10.25-0.01-0.10%23.95PE
Quotes are at least 15-min delayed：2025/07/04 10:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.